Mirae Asset Global Investments Co., Ltd. Halozyme Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $24 Billion
- Q4 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,240 shares of HALO stock, worth $246,386. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,240
Previous 4,582
7.46%
Holding current value
$246,386
Previous $262,000
22.9%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding HALO
# of Institutions
545Shares Held
121MCall Options Held
419KPut Options Held
172K-
Black Rock Inc. New York, NY17.6MShares$1.02 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$772 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$385 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$236 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.07MShares$178 Million0.05% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.09B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...